# Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

> **NCT03765775** · PHASE2 · UNKNOWN · sponsor: **First Hospital of Shijiazhuang City** · enrollment: 20 (estimated)

## Conditions studied

- Carcinoma
- Non-small Cell Lung Cancer
- Lung Neoplasm

## Interventions

- **BIOLOGICAL:** Sintilimab
- **DRUG:** Anlotinib Hydrochloride

## Key facts

- **NCT ID:** NCT03765775
- **Lead sponsor:** First Hospital of Shijiazhuang City
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-20
- **Primary completion:** 2019-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03765775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03765775, "Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03765775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*